Schrag presents, PATHFINDER, a prospective study in a screening population that evaluated the clinical feasibility of multi-cancer early detection blood testing at ESMO 2022.

These new tests use cfDNA and machine learning to detect a common cancer signal across >50 cancer types and predict cancer signal origin

The results showed multi-cancer early detection blood testing was feasible in outpatient practice without significant after effects and with a PPV of approximately 40%. Studies to refine multi-cancer screening techniques are ongoing.